Integrated Filing — IndAS



General information about company
Scrip Code 506820
NSE Symbol ASTRAZEN
MSEI Symbol NA
ISIN INE203A01020
Name of company ASTRAZENECA PHARMA INDIA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 30-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 16-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Healthcare
Start date and time of board meeting 30-May-2025   14:30:00
End date and time of board meeting 30-May-2025   17:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-02-11
Indicate Company website link for updated RPT policy of the Company https://www.astrazeneca.in/content/dam/az-in/pdf/2025/investor_relations_section_DU/Policy%20on%20Related%20Party%20Transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The disclosure for the default on loans and debt securities is not applicable to the entity.



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 4804800000 17162900000
Other income 161500000 406300000
Total income 4966300000 17569200000
2 Expenses
(a) Cost of materials consumed 942500000 2871300000
(b) Purchases of stock-in-trade 2878600000 10088200000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -1225000000 -3329400000
(d) Employee benefit expense 660700000 2574400000
(e) Finance costs 6800000 14600000
(f) Depreciation, depletion and amortisation expense 176900000 399900000
(f) Other Expenses
1 Allowance for expected credit loss (net) -9400000 6600000
2 Selling, marketing and distribution expenses 220200000 848700000
3 Other Expenses 473500000 1563400000
Total other expenses 684300000 2418700000
Total expenses 4124800000 15037700000
3 Total profit before exceptional items and tax 841500000 2531500000
4 Exceptional items -56800000 -967900000
5 Total profit before tax 784700000 1563600000
6 Tax expense
7 Current tax 229200000 605400000
8 Deferred tax -27000000 -199200000
9 Total tax expenses 202200000 406200000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 582500000 1157400000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 582500000 1157400000
17 Other comprehensive income net of taxes 14600000 -11700000
18 Total Comprehensive Income for the period 597100000 1145700000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 50000000 50000000
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 7653300000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 23.3 46.3
Diluted earnings (loss) per share from continuing operations 23.3 46.3
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 23.3 46.3
Diluted earnings (loss) per share from continuing and discontinued operations 23.3 46.3
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) Notes: n1.tThe Statements of Financial results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India. n2.tThe Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no segment information has been provided. n3.tExceptional Items na)tExceptional items for the year ended 31 March 2025 consists of employee separation cost amounting to Rs. 331.5 Million for restructuring of Biopharmaceuticals Business Unit in line with strategy of the Company to become a specialist focussed organisation, bring innovative medicines faster and transform patient outcome. nb)tDuring the previous year, the Company had made an announcement to Stock exchanges about its intention to exit the Company’s manufacturing site in Bangalore in due course of time. The Company had subsequently started exploring the option to sell the manufacturing site in a fully operational manner to a Contract Manufacturing Organization (CMO). However, on June 21, 2024, the Board resolved that the Company would instead, explore to find a suitable buyer for its manufacturing site and exit in due course. The operations at the manufacturing site is continuing as at March 31, 2025 and is expected to cease during the financial year 2025-26.The Company has estimated and accounted for expense amounting to Rs.56.8 Million for the quarter ended March 31, 2025 and Rs.636.4 Million in relation to the closure of manufacturing site, in accordance with the relevant Indian accounting standards. nc)tThe Company had entered into an Advance Pricing Agreement with Central Board of Direct Taxation for financial years 2015-2016 to 2019-2020 for which there were certain previously disclosed disputed Transfer Pricing matters consequent to which an amount of Rs.164.3 Million is disclosed as an exceptional income for the year ended 31 March 2024. n4.tThe figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between the audited figures in respect of the full financial years and the published unaudited year-to-date figures up to the third quarter of the respective financial years which were subjected to limited review by the statutory auditors. n5.tThe Board of Directors, at its meeting dated 30 May 2025, have recommended a final dividend of Rs. 32 per equity share aggregating to Rs. 800 Million which is subject to approval of shareholders at the ensuing Annual General Meeting . n6.tThis Statement of financial results, Statement of assets and liabilities and Statement of cash flows were reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 30 May 2025. n7.tThe Company has decided to change the rounding off principle followed in the Statement of financial results from lakhs of rupees to millions of rupees from the quarter ended 30 June 2024. n n nFor AstraZeneca Pharma India Limited n n nSanjeev Kumar Panchal nManaging Director n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 635800000
Capital work-in-progress 0
Investment property 0
Goodwill 0
Other intangible assets 6600000
Intangible assets under development 0
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 0
Trade receivables, non-current 0
Loans, non-current 1100000
Other non-current financial assets 80300000
Total non-current financial assets 81400000
Deferred tax assets (net) 415600000
Other non-current assets 618300000
Total non-current assets 1757700000
2 Current assets
Inventories 5485000000
Current financial asset
Current investments 0
Trade receivables, current 1848800000
Cash and cash equivalents 5361400000
Bank balance other than cash and cash equivalents 5600000
Loans, current 3000000
Other current financial assets 158000000
Total current financial assets 7376800000
Current tax assets (net) 0
Other current assets 561700000
Total current assets 13423500000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 15181200000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 50000000
Other equity 7653500000
Total equity attributable to owners of parent 7703500000
Non controlling interest
Total equity 7703500000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 294500000
Total non-current financial liabilities 294500000
Provisions, non-current 63200000
Deferred tax liabilities (net) 0
Deferred government grants, Non-current 0
Other non-current liabilities 90000000
Total non-current liabilities 447700000
Current liabilities
Current financial liabilities
Borrowings, current 0
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 25300000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 4537700000
Total Trade payable 4563000000
Other current financial liabilities 315500000
Total current financial liabilities 4878500000
Other current liabilities 979800000
Provisions, current 1065300000
Current tax liabilities (Net) 106400000
Deferred government grants, Current 0
Total current liabilities 7030000000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 7477700000
Total equity and liabilites 15181200000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Re-measurement gains/(losses) on post employment benefit obligations 19600000 -15600000
Total Amount of items that will not be reclassified to profit and loss 19600000 -15600000
2 Income tax relating to items that will not be reclassified to profit or loss 5000000 -3900000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income 14600000 -11700000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1563600000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 14600000
Adjustments for decrease (increase) in inventories -3206200000
Adjustments for decrease (increase) in trade receivables, current -316800000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -282600000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current -52500000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 2598000000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 292700000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 399900000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 4600000
Adjustments for provisions, current 3400000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current -68200000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains -7400000
Adjustments for dividend income 0
Adjustments for interest income 315600000
Adjustments for share-based payments 51400000
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow -3200000
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 619800000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -268100000
Net cash flows from (used in) operations 1295500000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 641900000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 653600000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 7100000
Purchase of property, plant and equipment 17500000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 318400000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) investing activities 308000000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Payments of lease liabilities 55300000
Dividends paid 600000000
Interest paid 600000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -655900000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 305700000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 305700000
Cash and cash equivalents cash flow statement at beginning of period 5055700000
Cash and cash equivalents cash flow statement at end of period 5361400000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Price Waterhouse & Co Chartered Accountants LLP Yes 30-Nov-2026


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 AstraZeneca Pharma India Limited AstraZeneca UK Limited, United Kingdom Holding Company of AstraZeneca Treasury Limited,nUnited Kingdom Purchase of goods or services NA 4899200000 963180000 2236900000
2 AstraZeneca Pharma India Limited AstraZeneca AB, Sweden Holding Company of AstraZeneca Pharmaceuticals AB,nSweden Sale of goods or services NA 631900000 199240000 378800000
3 AstraZeneca Pharma India Limited AstraZeneca AB, Sweden Holding Company of AstraZeneca Pharmaceuticals AB,nSweden Purchase of goods or services NA 1452300000 452480000 654600000
4 AstraZeneca Pharma India Limited AstraZeneca UK Limited, United Kingdom Holding Company of AstraZeneca Treasury Limited,nUnited Kingdom Any other transaction Payment towards reimbursement of expenses NA 9900000 0 0
5 AstraZeneca Pharma India Limited AstraZeneca Pty Ltd, Australia Fellow subsidiary Any other transaction Payment towards reimbursement of expenses NA 0 0 0
6 AstraZeneca Pharma India Limited AstraZeneca UK Limited, United Kingdom Holding Company of AstraZeneca Treasury Limited,nUnited Kingdom Any other transaction Recovery of reimbursable expenses NA 125500000 66750000 102300000
7 AstraZeneca Pharma India Limited AstraZeneca FZ LLC, Dubai Fellow subsidiary Any other transaction Recovery of reimbursable expenses NA 4000000 8610000 0
8 AstraZeneca Pharma India Limited AstraZeneca Singapore Pte Ltd, Singapore Fellow subsidiary Any other transaction Recovery of reimbursable expenses NA 8400000 3060000 5300000
9 AstraZeneca Pharma India Limited AstraZeneca Pharmaceuticals (Pty) Limited, South Africa Fellow subsidiary Any other transaction Recovery of reimbursable expenses NA 6300000 0 6300000
10 AstraZeneca Pharma India Limited AstraZeneca Pharmaceuticals (Phils) Inc, Philippines Fellow subsidiary Any other transaction Recovery of reimbursable expenses NA 0 0 0
11 AstraZeneca Pharma India Limited AstraZeneca UK Limited, United Kingdom Holding Company of AstraZeneca Treasury Limited,nUnited Kingdom Any other transaction Employee Share Compensation expenses NA -4100000 4090000 0
12 AstraZeneca Pharma India Limited P.T. AstraZeneca Indonesia Fellow subsidiary Any other transaction Recovery of reimbursable expenses NA 5200000 3780000 3400000
13 AstraZeneca Pharma India Limited AstraZeneca Pharmaceuticals Limited, Kenya Fellow subsidiary Any other transaction Recovery of reimbursable expenses NA 8200000 0 6400000
14 AstraZeneca Pharma India Limited AstraZeneca Pharma India Limited Employees Gratuity Fund Trust Employees' Benefit Plan Any other transaction Contribution to Trust NA 0 0 0
15 AstraZeneca Pharma India Limited AstraZeneca Pharma India Limited Management Staff Provident Fund Trust Employees' Benefit Plan Any other transaction Contribution to Trust NA 68000000 0 0
16 AstraZeneca Pharma India Limited AstraZeneca Pharma India Limited Management Staff Superannuation Fund Trust Employees' Benefit Plan Any other transaction Contribution to Trust NA 3600000 0 0
17 AstraZeneca Pharma India Limited Mr. Sanjeev Kumar Panchal Managing Director Any other transaction Short term Employee Benefits NA 25300000 0 0
18 AstraZeneca Pharma India Limited Mr. Sanjeev Kumar Panchal Managing Director Any other transaction Long term Employee Benefits NA 1300000 0 0
19 AstraZeneca Pharma India Limited Mr. Sanjeev Kumar Panchal Managing Director Any other transaction Post Employment Benefit NA -20200000 0 0
20 AstraZeneca Pharma India Limited Mr. Sanjeev Kumar Panchal Managing Director Any other transaction Employee Share Compensation Expenses NA 6600000 0 0
21 AstraZeneca Pharma India Limited Ms. Bhavana Agarwal Director and Chief Financial Officer Any other transaction Short term Employee Benefits NA 13700000 0 0
22 AstraZeneca Pharma India Limited Ms. Bhavana Agarwal Director and Chief Financial Officer Any other transaction Long term Employee Benefits NA 400000 0 0
23 AstraZeneca Pharma India Limited Ms. Bhavana Agarwal Director and Chief Financial Officer Any other transaction Post Employment Benefit NA -100000 0 0
24 AstraZeneca Pharma India Limited Ms. Bhavana Agarwal Director and Chief Financial Officer Any other transaction Employee Share Compensation Expenses NA 300000 0 0
25 AstraZeneca Pharma India Limited Ms. Manasa. R Company Secretary Any other transaction Short term Employee Benefits NA 2000000 0 0
26 AstraZeneca Pharma India Limited Ms. Manasa. R Company Secretary Any other transaction Long term Employee Benefits NA 100000 0 0
27 AstraZeneca Pharma India Limited Ms. Manasa. R Company Secretary Any other transaction Post Employment Benefit NA -700000 0 0
28 AstraZeneca Pharma India Limited Ms. Manasa. R Company Secretary Any other transaction Employee Share Compensation Expenses NA 0 0 0
29 AstraZeneca Pharma India Limited Mr. Narayan K Seshadri Independent Director Any other transaction Sitting fees paid to independent directors NA 200000 0 0
30 AstraZeneca Pharma India Limited Ms. Revathy Ashok Independent Director Any other transaction Sitting fees paid to independent directors NA 1600000 0 0
31 AstraZeneca Pharma India Limited Ms. Shilpa Divekar Nirula Independent Director Any other transaction Sitting fees paid to independent directors NA 1100000 0 0
32 AstraZeneca Pharma India Limited Ms. Monica Widhani Independent Director Any other transaction Sitting fees paid to independent directors NA 500000 0 0
33 AstraZeneca Pharma India Limited AstraZeneca Pharmaceuticals AB, Sweden Holding Company Any other transaction Dividend Paid NA 450000000 0 0
34 AstraZeneca Pharma India Limited Ms. Monica Widhani Independent Director Any other transaction Dividend Paid NA 0 0 0
Total value of transaction during the reporting period 7700500000